1088 results about "Chain length" patented technology

The present invention provides a method of stimulating a subterranean formation penetrated by a well. The formation has a water-bearing section and a hydrocarbon-bearing section. The method includes the steps of: (a) introducing into the formation an aqueous treatment fluid containing a hydrophobically-modified relative permeability modifier, and (b) introducing an acidizing treatment fluid into the formation. The hydrophobically-modified RPM can be formed and introduced into the formation in several ways. For example, the hydrophobically-modified RPM can be the reaction product of a hydrophilic polymer and a hydrophobic compound that are capable of reacting with each other. The hydrophilic polymer is a polymer containing reactive amino groups in the polymer backbone or as pendant groups, which are capable of reacting with a hydrophobic alkyl halide compound. The hydrophobically-modified RPM can include, for example, a polymer of DMAEMA quaternized with an alkyl halide, wherein the alkyl halide has an alkyl chain length of 6 to 22 carbons.

The present invention is directed to processes for the direct conversion of lipidic biomass fuelstock to combustible fuels. In particular, the invention provides a process for the direct conversion of animal fats to transportations fuels suitable as replacement for petroleum-derived transportation fuels. In one embodiment, the method comprises the steps of hydrolyzing a lipidic biomass to form free fatty acids, catalytically deoxygenating the free fatty acids to form n-alkanes, and reforming at least a portion of the n-alkanes into a mixture of compounds in the correct chain length, conformations, and ratio to be useful transportation fuels. Particularly, the product prepared according to the invention comprises mixtures of hydrocarbon compounds selected from the group consisting of n-alkanes, isoalkanes, aromatics, cycloalkanes, and combinations thereof.

The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.

The present invention provides a solid catalyst component for the polymerization of olefins, comprising magnesium, titanium, a halogen and an electron donor, wherein said electron donor comprises at least one selected from the group consisting of polyol ester compounds of the formula (I): R1CO—O—CR3R4-A-CR5R6—O—CO—R2 (I) wherein, R1 and R2 groups, which may be identical or different, can be substituted or unsubstituted hydrocarbyl having 1 to 20 carbon atoms, R3-R6 groups, which may be identical or different, can be selected from the group consisting of hydrogen, halogen or substituted or unsubstituted hydrocarbyl having 1 to 20 carbon atoms, R1-R6 groups optionally contain one or more hetero-atoms replacing carbon, hydrogen atom or the both, said hetero-atom is selected from the group consisting of nitrogen, oxygen, sulfur, silicon, phosphorus and halogen atom, two or more of R3-R6 groups can be linked to form saturated or unsaturated monocyclic or polycyclic ring; A is a single bond or bivalent linking group with chain length between two free radicals being 1-10 atoms, wherein said bivalent linking group is selected from the group consisting of aliphatic, alicyclic and aromatic bivalent radicals, and can carry C1-C20 linear or branched substituents; one or more of carbon atom and / or hydrogen atom on above-mentioned bivalent linking group and substituents can be replaced by a hetero-atom selected from the group consisting of nitrogen, oxygen, sulfur, silicon, phosphorus, and halogen atom, and two or more said substituents on the linking group as well as above-mentioned R3-R6 groups can be linked to form saturated or unsaturated monocyclic or polycyclic ring.

The invention provides a compound of the formula (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase: wherein A is a group R2 or CH2—R2 where R2 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; B is a bond or an acyclic linker group having a linking chain length of up to 3 atoms selected from C, N, S and O; R1 is hydrogen or a group selected from SO2Rb, SO2NR7R8, CONR7R8, NR7R9 and carbocyclic and heterocyclic groups having from 3 to 7 ring members; R3, R4, R5 and R6 are the same or different and are each selected from hydrogen, halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group Ra—Rb wherein Ra is a bond, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2; and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; Rc is hydrogen or C1-4 hydrocarbyl; X1 is O, S or NRc and X2 is ═O, ═S or ═NRc; R7 is selected from hydrogen and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; R8 is selected from R7 and carbocyclic and heterocyclic groups having from 3 to 12 ring members; R9 is selected from R8, COR8 and SO2R8; or NR7R8 or NR7R9 may each form a heterocyclic group having from 5 to 12 ring members; but excluding the compounds N-[(morpholin-4-yl)phenyl-1H-indazole-3-carboxamide and N-[4-(acetylaminosulphonyl)phenyl-1H-indazole-3-carboxamide.

Hydrocarbon and hydrogen fuels and other products may be produced by a process employing a combination of fermentation and electrochemical stages. In the process, a biomass contained within a fermentation medium is fermented with an inoculum comprising a mixed culture of microorganisms derived the rumen contents of a rumen-containing animal. This inoculated medium is incubated under anaerobic conditions and for a sufficient time to produce volatile fatty acids. The resultant volatile fatty acids are then subjected to electrolysis under conditions effective to convert said volatile fatty acids to hydrocarbons and hydrogen simultaneously. The process can convert a wide range of biomass materials to a wide range of volatile fatty acid chain lengths and can convert these into a wide range of biobased fuels and biobased products.

There is provided a water-base ink composition which has excellent ejection stability and can be evenly printed on recording media. The water-base ink composition comprises at least: a colorant component selected from dyes and pigments; a monovalent or divalent branched alcohol with C5 to C10 chain length; an acetylene glyco surfactant and / or a penetrating organic solvent; a humectant; and water. The monovalent or divalent branched alcohol with C5 to C10 chain length, the acetylene glycol surfactant and / or the penetrating organic solvent, and the humectant are selected from combinations of branched alcohols, acetylene glycol surfactants and / or penetrating organic solvents, and humectants which are miscible with one another.

The invention provides a compressed convolutional neural network-oriented parallel convolution operation method and apparatus. The method comprises the steps of determining an adopted operation mode according to input control signal convolution data shift chain length selection, accumulated offset enabling and convolution calculation enabling; and by adopting two serial shift register chains, inputting convolution data, convolution parameters and channel offset, and performing 3X3 and 1X1 convolution operation at the same time for a same input convolution data stream. According to the method, a multiplier, an accumulator, a parameter register and an offset register are added only based on original serial shift register chain-based 3X3 convolution operation; the realization method is simple; the executive efficiency is high; and the convolution operation in a compressed neural network algorithm can be effectively accelerated. According to the apparatus, a plurality of characteristic graphs can be output at the same time through simple hardware unit expansion and copying; and the apparatus has the advantages of low power consumption, high function unit utilization rate and high processing speed.

The present invention provides novel dietary supplement compositions based on the use of a particular oil phase which comprises of Coenzyme Q10 and optionally other lipophilic dietary ingredients of low water solubility and a liquid mixture which comprises one or more emulsifiers, a fatty acid monoester formed between an short chain alcohol of C1 to C4 chain length and a saturated, or mono-unsaturated, or di-unsaturated (both conjugated and non-conjugated) fatty acid of C6 to C24 chain length, or medium chain mono- / di-esters, or the mixture of above. The composition is in a form of self-emulsifiable in the aqueous medium, for example, a simulated gastric fluid, which should provide a high oral bioavailability for the lipophilic dietary ingredients.

The invention provides liquid cleanser compositions which can use fatty acyl isethionates surfactant products, regardless of free fatty acid and / or fatty acid salt content of isethionate mixture or chain length distribution of isethionates mixture. The key is to insure a specific combination of liquid crystal inducer (of surfactant phase) and of modifier so that the isethionates will be stable at low and high temperatures.

The present invention provides a method of stimulating a subterranean formation penetrated by a well. The formation has a water-bearing section and a hydrocarbon-bearing section. The method includes the steps of: (a) introducing into the formation an aqueous treatment fluid containing a hydrophobically-modified relative permeability modifier, and (b) introducing an acidizing treatment fluid into the formation. The hydrophobically-modified RPM can be formed and introduced into the formation in several ways. For example, the hydrophobically-modified RPM can be the reaction product of a hydrophilic polymer and a hydrophobic compound that are capable of reacting with each other. The hydrophilic polymer is a polymer containing reactive amino groups in the polymer backbone or as pendant groups, which are capable of reacting with a hydrophobic alkyl halide compound. The hydrophobically-modified RPM can include, for example, a polymer of DMAEMA quaternized with an alkyl halide, wherein the alkyl halide has an alkyl chain length of 6 to 22 carbons.

The present invent relates to sustained release and long residing ophthalmic formulation having thermosensitivity, mucoadhesiveness, hydro gel properties and small particle size. The said formulation comprises of micelle solution of random block co-polymer having a hydrophobic component and a hydrophilic component of general formula -(X+Y+Z-)m, wherein m is an integer greater than 2 X is a monomer which will provide hydrogel formation properties of the co-polymer to reduce the irritability of the eye and is selected from vinyl group of compounds Y is a monomer which will provide thermosensitivity properties of the co-polymer having a general formula R1-R2N-(C=O)-CH=CH2, R1=a proton or CnH2n+1 in which n may have the value from 3 to 6 and R2=alkyl group having chain length of C3 to C6 Z is a monomer which will provide mucoadhesiveness and pH-sensitivity properties to the co-polymer and is selected from acrylate based monomers at least one hydrophobic drug with the said block co-polymer solution; The invention also provides a process of preparing said formulation.

This invention relates to antimicrobial wound dressings having a non-leaching antimicrobial activity, releasable antimicrobial and antiprotease agents, and a controlled-release bioactive agent such as doxycycline. The Wound dressing material is absorbent and acts as a substrate for antimicrobial and antiprotease agents as well as bioactive agents. More generally, this invention relates to methods and compositions for materials having a non-leaching coating that has antimicrobial properties. The coating is applied to substrates such as gauze-type wound dressings, powders and other substrates. Covalent, non-leaching, non-hydrolyzable bonds are formed between the substrate and the polymer molecules that form the coating. A high concentration of anti-microbial groups on multi-length polymeric molecules and relatively long average chain lengths, contribute to an absorbent or superabsorbent surface with a high level antimicrobial efficacy. Utilization of non-leaching coatings having a plurality of anionic or cationic sites is used according to this invention to bind a plurality of oppositely charged biologically or chemically active compounds, and to release the bound oppositely charged biologically or chemically active compounds from said substrate over a period of time to achieve desired objectives as diverse as improved wound healing to reduction in body odor.

Disclosed is a method and a medical device comprising a bio-compatible polymeric product with a layered structure comprising at least one upper layer of a first polymeric component, a middle layer of a second polymeric component, and at least one lower layer of a third polymeric component, wherein the chain length of the first polymeric component and the third polymeric component is longer than the chain length of the second polymeric component. The medical device combines the features of strength, durability and bio-compatibility as well as it has resistance to tear and wear and has a good compressibility. A preferred design of the medical device is a cup produced from a care or film of LDPE surrounded by two layers of UHMWPE fabric. The medical device can be used as implants in mammals, especially as artificial cartilage within joints to secure mobility of the joint.

The present invention relates to a method and a device for alleviating and / or preventing conditions relating to damaged joints involving articulating surfaces. In a first aspect the present invention relates to a prosthetic device for insertion into a joint cavity of a joint of a vertebrate, such as a human, said device consisting of a biocompatible material comprising at least a first polymeric component and a second polymeric component, wherein the chain length of the first polymeric component is longer than the chain length of the second polymeric component, the polymeric components in particular being polyethylene, polypropylene and / or polyvinylpyrrolidone. The device may be used for establishing slidability and / or distributing pressure in a joint of a vertebrate such as a human, by inserting into the joint cavity of the joint a prosthetic device, preferably a prosthetic device as defined in this invention, capable of locking itself to an intra-articular component and thereby being fixed or retained in the joint cavity in a manner which is substantially non-invasive with respect to cartilage and bone natively present in the joint cavity. The device may be formed by moulding, whereby it is possible to adapt the form of the device to the joint needing alleviation. Also the device may be formed with a hole or a slit to fit into the joint and lock the device around intra-articular components. A further aspect of invention relates to a method for introducing the prosthetic device into a joint, such as a method comprising locking the device to an intro-articular component, thereby fixing or retaining the device in the joint cavity in a manner which is substantially non-invasive with respect to cartilage and bone natively present in the joint cavity. Also the invention relates to an instrument for inserting a prosthetic device according to the invention, comprising means for deforming the prosthetic device into a reduced volume or a slender shape and means for grasping the intra-articular component to which the device is capable of interlocking.

The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

The present invention relates to polyglycerol partial esers of polyhydroxystearic acid and polyfunctional carboxylic acids which are obtainable by esterification of a polyglycerol mixture with polyhydroxystearic acid where N=1 to 10, preferably 2 to 8, in particular 3 to 5 units and dimer fatty acids which have been obtained by catalytic dimerization of unsaturated fatty acids having 12 to 22 C atoms and have an average functionality of 2 to 3, and / or with aliphatic, linear or branched dicarboxylic acids having a chain length of 2 to 16 C atoms and additionally saturated or unsaturated, linear or branched fatty acids having 6 to 22 C atoms, preferably 12 to 18 C atoms, the degree of esterification of the polyglycerol mixture being between 20 and 75%, preferably 40 to 70%.

Disclosed are carriers for drugs and / or MR imaging agents having a lipid bilayer shell comprising a phospholipid having two terminal alkyl chains, one being a short chain having a chain length of at most seven carbon atoms, the other being a long chain having a chain length of at least fifteen carbon atoms. The mixed long / short chain phospholipids serve to tune the release properties of the carrier. Preferred phospholipids are phosphatidylcholines.

A process comprising polymerizing at least one fluorinated monomer in an aqueous medium containing initiator and polymerization agent to form an aqueous dispersion of particles of fluoropolymer, the polymerization agent comprising: fluoropolyether acid or salt thereof having a number average molecular weight of at least about 800 g / mol; and fluorosurfactant having the formula: [R1—On-L-A−]Y+wherein: R1 is a linear or branched partially or fully fluorinated aliphatic group which may contain ether linkages; n is 0 or 1; L is a linear or branched alkylene group which may be nonfluorinated, partially fluorinated or fully fluorinated and which may contain ether linkages; A− is an anionic group selected from the group consisting of carboxylate, sulfonate, sulfonamide anion, and phosphonate; and Y+ is hydrogen, ammonium or alkali metal cation; with the proviso that the chain length of R1—On-L- is not greater than 6 atoms.

Abstract of Disclosure The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula wherein A is an amino acid having at least one functional group in the side chain;B is a chemical compound covalently bound to a functional group of the side chain of A, chosen from the group consisting of (a) oligopeptides having a chain length of up to 20 amino acids, (b) homopolymers of glycine consisting of up to 6 glycine monomers, and (c) polyethylene glycols having molar masses of up to 20 000 g / mol; and C is a group amide-bonded to A chosen from the group consisting of thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine. The invention further relates to the use of said compounds for targeted intervention in local immunological processes (chemotaxis, inflammatory processes, autoimmune diseases), as well as effective and targeted treatment of pathophysiological and physiological processes related thereto (psoriasis, periodontitis, arthritis, allergies, inflammation), inter alia.

This invention relates to methods and compositions for materials having a non-leaching coating that has antimicrobial properties. The coating is applied to substrates such as gauze-type wound dressings, powders and other substrates. Covalent, non-leaching, non-hydrolyzable bonds are formed between the substrate and the polymer molecules that form the coating. A high concentration of anti-microbial groups on multi-length polymer chains and relatively long average chain lengths, contribute to an absorbent or superabsorbent surface with a high level antimicrobial efficacy. Utilization of non-leaching coatings having a plurality of anionic or cationic sites is used according to this invention to bind a plurality of oppositely charged biologically or chemically active compounds, and to release the bound oppositely charged biologically or chemically active compounds from said substrate over a period of time to achieve desired objectives as diverse as improved wound healing to reduction in body odor.

The present invention relates to an aqueous oral composition comprising:a) from 0.2% to 3% divalent metal ions comprising:i. from 0.1% to 1.5% of zinc ions;ii. from 0.1% to 2% of tin (II) ions; andb) a source of fluoride ions;c) a silica dental abrasive;d) one or more chelants having a MW of less than 1000 and capable of forming water-soluble complexes with the zinc ions, wherein the chelants comprise less than 0.2% linear polyphosphates having a chain length of four or more;e) an orally acceptable carrier comprising at least 20% total water;wherein the pH of the composition is from 5 to 6.5, the molar ratio of the chelants to the divalent metal ions is at least 0.70:1 and at least 80% by weight of the total zinc ions are solubilised within the composition.The composition of the invention has been found to give improved antimicrobial activity from the zinc / stannous combination without significant taste, staining or stability problems, compared to compositions having lower levels of chelants.

Glycerol-3-phosphate o-acyltransferase (GPAT) participates in the first step of oil biosynthesis and is expected to play a key role in altering the quantity of long-chain polyunsaturated fatty acids (PUFAs) produced in oils of oleaginous organisms. The present application provides a nucleic acid fragment isolated from Mortierella alpina encoding a GPAT that is suitable for use in the manufacture of oils enriched in omega fatty acids in oleaginous organisms. Most desirably, the substrate specificity of the instant GPAT will be particularly useful to enable accumulation of long-chain PUFAs having chain lengths equal to or greater than C20 in oleaginous yeast, such as Yarrowia lipolytica.